AKTS vs MYGN
AKTS: Aktis Oncology is developing next-generation targeted radiopharmaceuticals using a proprietary miniprotein platform to deliver alpha-emitting radioisotopes to hard-to-treat solid tumors. MYGN: Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health, and mental health to guide clinical decisions and improve patient outcomes.
Side-by-side fundamentals
| Metric | AKTS | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.81 | $5.66 | |
| Market cap as of 2026-07-23 | $1.4B | $547M | |
| PEG as of 2026-07-23 | n/a | -0.00 | |
| Net margin as of 2026-07-23 | -843.9% | -48.2% | MYGN higher |
| Gross margin as of 2026-07-23 | -11.6% | +70.0% | MYGN higher |
| Operating margin as of 2026-07-23 | -1001.5% | -46.9% | MYGN higher |
| ROE as of 2026-07-23 | -47.5% | -109.1% | AKTS higher |
| ROA as of 2026-07-23 | -24.1% | -57.4% | AKTS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.36 | AKTS lower |
| Revenue growth (YoY) as of 2026-07-23 | +49.9% | -0.3% | AKTS higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +6.7% | |
| Beta as of 2026-07-23 | 160.04 | 1.62 | |
| 1-year return as of 2026-07-22 close | -82.5% | +23.3% | MYGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.